Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
Organon Announces Proposed $1.0 Billion Senior Notes Offering
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
Organon Reports Results for the First Quarter Ended March 31, 2024
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
Feb 23 (Reuters) - The attorney general for one of the most populous U.S. states this week urged federal drug regulators to address safety risks associated with the widely used asthma and allergy medicine Singulair, saying current warnings on the drug's packaging are insufficient, particularly for children.
Organon Announces HADLIMA Has Been Selected by the US Department of VA
Organon's Humira biosimilar gets exclusive spot on VA formulary